| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
26008 |
| Drug |
Niraparib + abiraterone acetate |
| Brand |
Akeega® |
| Indication |
Niraparib + abiraterone acetate (Akeega®) in combination with androgen deprivation therapy (ADT) is indicated for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) and BRCA 1/2 mutations (germline and/or somatic). |
| Rapid review commissioned |
06/03/2026 |
| Rapid review completed |
30/03/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of niraparib + abiraterone acetate (Akeega®) compared with the current standard of care. |
| Full HTA commissioned by the HSE |
01/04/2026 |
| Pre-submission consultation with Applicant |
19/05/2026 |
